XyloCor Therapeutics, Inc.
XyloCor is a clinical-stage biotechnology company dedicated to developing first-in-class gene therapies for patients with cardiovascular disease. The company’s lead product comprises the use of vascular endothelial growth factor for the treatment of diffuse coronary artery disease.
Location: New York, NY
Foundation Cornell Technology Licensed: 2015